Suppr超能文献

溶原缺陷噬菌体作为控制细菌感染的新型治疗剂。

Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection.

机构信息

Gangagen Biotechnologies Pvt Ltd, No, 12, 5th Cross, Raghavendra Layout, Tumkur Road, Yeshwantpur, Bangalore-560 022, India.

出版信息

BMC Microbiol. 2011 Aug 31;11:195. doi: 10.1186/1471-2180-11-195.

Abstract

BACKGROUND

Interest in phage therapy has grown over the past decade due to the rapid emergence of antibiotic resistance in bacterial pathogens. However, the use of bacteriophages for therapeutic purposes has raised concerns over the potential for immune response, rapid toxin release by the lytic action of phages, and difficulty in dose determination in clinical situations. A phage that kills the target cell but is incapable of host cell lysis would alleviate these concerns without compromising efficacy.

RESULTS

We developed a recombinant lysis-deficient Staphylococcus aureus phage P954, in which the endolysin gene was rendered nonfunctional by insertional inactivation. P954, a temperate phage, was lysogenized in S. aureus strain RN4220. The native endolysin gene on the prophage was replaced with an endolysin gene disrupted by the chloramphenicol acetyl transferase (cat) gene through homologous recombination using a plasmid construct. Lysogens carrying the recombinant phage were detected by growth in presence of chloramphenicol. Induction of the recombinant prophage did not result in host cell lysis, and the phage progeny were released by cell lysis with glass beads. The recombinant phage retained the endolysin-deficient genotype and formed plaques only when endolysin was supplemented. The host range of the recombinant phage was the same as that of the parent phage. To test the in vivo efficacy of the recombinant endolysin-deficient phage, immunocompromised mice were challenged with pathogenic S. aureus at a dose that results in 80% mortality (LD80). Treatment with the endolysin-deficient phage rescued mice from the fatal S. aureus infection.

CONCLUSIONS

A recombinant endolysin-deficient staphylococcal phage has been developed that is lethal to methicillin-resistant S. aureus without causing bacterial cell lysis. The phage was able to multiply in lytic mode utilizing a heterologous endolysin expressed from a plasmid in the propagation host. The recombinant phage effectively rescued mice from fatal S. aureus infection. To our knowledge this is the first report of a lysis-deficient staphylococcal phage.

摘要

背景

由于细菌病原体对抗生素耐药性的迅速出现,过去十年人们对噬菌体治疗的兴趣日益浓厚。然而,由于噬菌体用于治疗目的可能引起免疫反应、噬菌体的裂解作用迅速释放毒素以及在临床情况下难以确定剂量,因此人们对噬菌体治疗的应用产生了担忧。一种既能杀死靶细胞又不能裂解宿主细胞的噬菌体可以减轻这些担忧,而不会影响疗效。

结果

我们开发了一种重组溶菌缺陷型金黄色葡萄球菌噬菌体 P954,其中溶菌酶基因通过插入失活而失去功能。P954 是一种温和噬菌体,在金黄色葡萄球菌 RN4220 菌株中被溶原化。通过使用带有氯霉素乙酰转移酶(cat)基因的质粒构建物进行同源重组,用 cat 基因破坏了原噬菌体上的天然溶菌酶基因,从而取代了该基因。在含有氯霉素的情况下进行培养,可以检测到携带重组噬菌体的溶原菌。重组噬菌体的诱导不会导致宿主细胞裂解,并且通过玻璃珠细胞裂解释放噬菌体后代。重组噬菌体保留了溶菌酶缺陷型基因型,只有在补充溶菌酶时才会形成噬菌斑。重组噬菌体的宿主范围与亲本噬菌体相同。为了测试重组溶菌酶缺陷型噬菌体的体内疗效,免疫功能低下的小鼠用导致 80%死亡率(LD80)的致病性金黄色葡萄球菌进行攻毒。用溶菌酶缺陷型噬菌体治疗可使小鼠免受致命性金黄色葡萄球菌感染。

结论

开发了一种重组溶菌酶缺陷型金黄色葡萄球菌噬菌体,该噬菌体对耐甲氧西林金黄色葡萄球菌具有致死性,而不会引起细菌细胞裂解。噬菌体能够以裂解模式繁殖,利用在繁殖宿主中表达的异源溶菌酶。重组噬菌体有效地挽救了致命性金黄色葡萄球菌感染的小鼠。据我们所知,这是首例溶菌酶缺陷型金黄色葡萄球菌噬菌体的报道。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec08/3224134/1bb4a000f178/1471-2180-11-195-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验